<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Combinatorial Chemistry &amp; High Throughput Screening</journal-id><journal-title-group><journal-title xml:lang="en">Combinatorial Chemistry &amp; High Throughput Screening</journal-title><trans-title-group xml:lang="ru"><trans-title>Combinatorial Chemistry &amp; High Throughput Screening</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1386-2073</issn><issn publication-format="electronic">1875-5402</issn><publisher><publisher-name xml:lang="en">Bentham Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">644124</article-id><article-id pub-id-type="doi">10.2174/0113862073295568240105025006</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Chemistry</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Nuclear Factor Kappa B: A Nobel Therapeutic Target of Flavonoids Against Parkinson's Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Niraj Kumar</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Ashini</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Mayank</surname><given-names></given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff id="aff1"><institution>Division of Pharmacology, Institute of Pharmaceutical Research,, GLA University</institution></aff><aff id="aff2"><institution>Division of Pharmacology, Institute of Pharmaceutical Research, GLA University</institution></aff><pub-date date-type="pub" iso-8601-date="2024-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2024</year></pub-date><volume>27</volume><issue>14</issue><issue-title xml:lang="ru"/><fpage>2062</fpage><lpage>2077</lpage><history><date date-type="received" iso-8601-date="2025-01-07"><day>07</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bentham Science Publishers</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bentham Science Publishers</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjpbr.com/1386-2073/article/view/644124">https://rjpbr.com/1386-2073/article/view/644124</self-uri><abstract xml:lang="en"><p id="idm46041443678592">Parkinson's disease (PD), the most common brain-related neurodegenerative disorder, is comprised of several pathophysiological mechanisms, such as mitochondrial dysfunction, neuroinflammation, aggregation of misfolded alpha-synuclein, and synaptic loss in the substantia nigra pars compacta region of the midbrain. Misfolded alpha-synuclein, originating from damaged neurons, triggers a series of signaling pathways in both glial and neuronal cells. Activation of such events results in the production and expression of several proinflammatory cytokines via the activation of the nuclear factor κB (NF-κB) signaling pathway. Consequently, this cascade of events worsens the neurodegenerative processes, particularly in conditions, such as PD and synucleinopathies. Microglia, astrocytes, and neurons are just a few of the many cells and tissues that express the NF-κB family of inducible types of transcription factors. The dual role of NF-κB activation can be crucial for neuronal survival, although the classical NF-κB pathway is important for controlling the generation of inflammatory mediators during neuroinflammation. Modulating NF-κB-associated pathways through the selective action of several agents holds promise for mitigating dopaminergic neuronal degeneration and PD. Several naturally occurring compounds in medicinal plants can be an effective treatment option in attenuating PD-associated dopaminergic neuronal loss via selectively modifying the NF-κB-mediated signaling pathways. Recently, flavonoids have gained notable attention from researchers because of their remarkable anti-neuroinflammatory activity and significant antioxidant properties in numerous neurodegenerative disorders, including PD. Several subclasses of flavonoids, including flavones, flavonols, isoflavones, and anthocyanins, have been evaluated for neuroprotective effects against in vitro and in vivo models of PD. In this aspect, the present review highlights the pathological role of NF-κB in the progression of PD and investigates the therapeutic potential of natural flavonoids targeting the NF-κB signaling pathway for the prevention and management of PD-like manifestations with a comprehensive list for further reference. Available facts strongly support that bioactive flavonoids could be considered in food and/or as lead pharmacophores for the treatment of neuroinflammation-mediated PD. Furthermore, natural flavonoids having potent pharmacological properties could be helpful in enhancing the economy of countries that cultivate medicinal plants yielding bioactive flavonoids on a large scale.</p></abstract><kwd-group xml:lang="en"><kwd>Parkinson&amp;amp</kwd><kwd>rsquo</kwd><kwd>s disease</kwd><kwd>NF-κB</kwd><kwd>neuroinflammation</kwd><kwd>flavonoid</kwd><kwd>neuroprotection</kwd><kwd>SNpc.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kowal, S.L.; Dall, T.M.; Chakrabarti, R.; Storm, M.V.; Jain, A. The current and projected economic burden of Parkinsons disease in the United States. Mov. Disord., 2013, 28(3), 311-318. doi: 10.1002/mds.25292 PMID: 23436720</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Singh, N.K.; Singh, A.; Varshney, M.; Agrawal, R. A research update on exendin-4 as a novel molecule against parkinsons disease. Curr. Mol. Med., 2023, 23(9), 889-900. doi: 10.2174/1566524023666230529093314 PMID: 37254536</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Davie, C.A. A review of Parkinsons disease. Br. Med. Bull., 2008, 86(1), 109-127. doi: 10.1093/bmb/ldn013 PMID: 18398010</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Goyal, A.; Verma, A.; Agrawal, A.; Dubey, N.; Kumar, A.; Behl, T. Therapeutic implications of crocin in Parkinsons disease: A review of preclinical research. Chem. Biol. Drug Des., 2023, 101(6), 1229-1240. doi: 10.1111/cbdd.14210 PMID: 36752710</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Surmeier, D.J. Determinants of dopaminergic neuron loss in Parkinsons disease. FEBS J., 2018, 285(19), 3657-3668. doi: 10.1111/febs.14607 PMID: 30028088</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bansal, K.; Singh, S.; Singh, V.; Bajpai, M. Nutraceuticals a food for thought in the treatment of parkinsons disease. Curr. Nutr. Food Sci., 2023, 19(9), 961-977. doi: 10.2174/1573401319666230515104325</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Goyal, A.; Verma, A.; Dubey, N.; Raghav, J.; Agrawal, A. Naringenin: A prospective therapeutic agent for Alzheimers and Parkinsons disease. J. Food Biochem., 2022, 46(12), e14415. doi: 10.1111/jfbc.14415 PMID: 36106706</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Verma, A.; Goyal, A. Reformative effect of daidzein on motor dysfunction following rotenone injection in ovariectomized rats. Rev. Bras. Farmacogn., 2022, 32(4), 563-574. doi: 10.1007/s43450-022-00277-3</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Amor, S.; Puentes, F.; Baker, D.; Van Der Valk, P. Inflammation in neurodegenerative diseases. Immunology, 2010, 129(2), 154-169. doi: 10.1111/j.1365-2567.2009.03225.x PMID: 20561356</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Tufekci, K.U.; Meuwissen, R.; Genc, S.; Genc, K. Inflammation in Parkinsons disease. Adv. Protein Chem. Struct. Biol., 2012, 88, 69-132. doi: 10.1016/B978-0-12-398314-5.00004-0 PMID: 22814707</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Monahan, A.J.; Warren, M.; Carvey, P.M. Neuroinflammation and peripheral immune infiltration in Parkinsons disease: An autoimmune hypothesis. Cell Transplant., 2008, 17(4), 363-372. doi: 10.3727/096368908784423328 PMID: 18522239</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Tansey, M.G.; Goldberg, M.S. Neuroinflammation in Parkinsons disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis., 2010, 37(3), 510-518. doi: 10.1016/j.nbd.2009.11.004 PMID: 19913097</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Pajares, M.I.; Rojo, A.; Manda, G.; Boscá, L.; Cuadrado, A. Inflammation in parkinsons disease: Mechanisms and therapeutic implications. Cells, 2020, 9(7), 1687. doi: 10.3390/cells9071687 PMID: 32674367</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Church, F.C. Treatment options for motor and non-motor symptoms of parkinsons disease. Biomolecules, 2021, 11(4), 612. doi: 10.3390/biom11040612 PMID: 33924103</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Karin, M.; Lin, A. NF-κB at the crossroads of life and death. Nat. Immunol., 2002, 3(3), 221-227. doi: 10.1038/ni0302-221 PMID: 11875461</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Li, Q.; Verma, I.M. NF-κB regulation in the immune system. Nat. Rev. Immunol., 2002, 2(10), 725-734. doi: 10.1038/nri910 PMID: 12360211</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Perkins, N.D. Integrating cell-signalling pathways with NF-κB and IKK function. Nat. Rev. Mol. Cell Biol., 2007, 8(1), 49-62. doi: 10.1038/nrm2083 PMID: 17183360</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Glass, C.K.; Saijo, K.; Winner, B.; Marchetto, M.C.; Gage, F.H. Mechanisms underlying inflammation in neurodegeneration. Cell, 2010, 140(6), 918-934. doi: 10.1016/j.cell.2010.02.016 PMID: 20303880</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Mattson, M.P.; Camandola, S. NF-κB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest., 2001, 107(3), 247-254. doi: 10.1172/JCI11916 PMID: 11160145</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Rocha, S.M.; Kirkley, K.S.; Chatterjee, D.; Aboellail, T.A.; Smeyne, R.J.; Tjalkens, R.B. Microglia-specific knock-out of NF-κB/IKK2 increases the accumulation of misfolded α-synuclein through the inhibition of p62/SEQUESTOSOME -1-dependent autophagy in the rotenone model of Parkinsons disease. Glia, 2023, 71(9), 2154-2179. doi: 10.1002/glia.24385 PMID: 37199240</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Liu, T.; Zhang, L.; Joo, D.; Sun, S.C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther., 2017, 2(1), 17023. doi: 10.1038/sigtrans.2017.23 PMID: 29158945</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Mattson, M.P.; Meffert, M.K. Roles for NF-κB in nerve cell survival, plasticity, and disease. Cell Death Differ., 2006, 13(5), 852-860. doi: 10.1038/sj.cdd.4401837 PMID: 16397579</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Salles, A.; Romano, A.; Freudenthal, R. Synaptic NF-kappa B pathway in neuronal plasticity and memory. J. Physiol. Paris, 2014, 108(4-6), 256-262. doi: 10.1016/j.jphysparis.2014.05.002 PMID: 24854662</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Dutta, D.; Jana, M.; Majumder, M.; Mondal, S.; Roy, A.; Pahan, K. Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo. Nat. Commun., 2021, 12(1), 5382. doi: 10.1038/s41467-021-25767-1 PMID: 34508096</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Shi, Z.M.; Han, Y.W.; Han, X.H.; Zhang, K.; Chang, Y.N.; Hu, Z.M.; Qi, H.X.; Ting, C.; Zhen, Z.; Hong, W. Upstream regulators and downstream effectors of NF-κB in Alzheimers disease. J. Neurol. Sci., 2016, 366, 127-134. doi: 10.1016/j.jns.2016.05.022 PMID: 27288790</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Srinivasan, M.; Lahiri, D.K. Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimers disease and multiple sclerosis. Expert Opin. Ther. Targets, 2015, 19(4), 471-487. doi: 10.1517/14728222.2014.989834 PMID: 25652642</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Singh, S.S.; Rai, S.N.; Birla, H.; Zahra, W.; Rathore, A.S.; Singh, S.P. NF-κB-mediated neuroinflammation in Parkinsons Disease and potential therapeutic effect of polyphenols. Neurotox. Res., 2020, 37(3), 491-507. doi: 10.1007/s12640-019-00147-2 PMID: 31823227</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Choy, K.W.; Murugan, D.; Leong, X.F.; Abas, R.; Alias, A.; Mustafa, M.R. Flavonoids as natural anti-inflammatory agents targeting nuclear factor-kappa B (NFκB) signaling in cardiovascular diseases: A mini review. Front. Pharmacol., 2019, 10, 1295. doi: 10.3389/fphar.2019.01295 PMID: 31749703</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Gasparini, L.; Ongini, E.; Wenk, G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimers disease: Old and new mechanisms of action. J. Neurochem., 2004, 91(3), 521-536. doi: 10.1111/j.1471-4159.2004.02743.x PMID: 15485484</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Al-Khayri, J.M.; Sahana, G.R.; Nagella, P.; Joseph, B.V.; Alessa, F.M.; Al-Mssallem, M.Q. Flavonoids as potential anti-inflammatory molecules: A review. Molecules, 2022, 27(9), 2901. doi: 10.3390/molecules27092901 PMID: 35566252</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Kaltschmidt, B.; Helweg, L.P; Greiner, J.F.W.; Kaltschmidt, C. NF-κB in neurodegenerative diseases: Recent evidence from human genetics. Front. Mol. Neurosci., 2022, 15, 954541. doi: 10.3389/fnmol.2022.954541 PMID: 35983068</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Ghosh, G.; Wang, V.Y.F.; Huang, D.B.; Fusco, A. NF-κB regulation: Lessons from structures. Immunol. Rev., 2012, 246(1), 36-58. doi: 10.1111/j.1600-065X.2012.01097.x PMID: 22435546</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Moynagh, P.N. The NF-κB pathway. J. Cell Sci., 2005, 118(20), 4589-4592. doi: 10.1242/jcs.02579 PMID: 16219681</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Gilmore, T.D. Introduction to NF-κB: Players, pathways, perspectives. Oncogene, 2006, 25(51), 6680-6684. doi: 10.1038/sj.onc.1209954 PMID: 17072321</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Cai, M.; Zhuang, W.; Lv, E.; Liu, Z.; Wang, Y.; Zhang, W.; Fu, W. Kaemperfol alleviates pyroptosis and microglia-mediated neuroinflammation in Parkinsons disease via inhibiting p38MAPK/NF-κB signaling pathway. Neurochem. Int., 2022, 152, 105221. doi: 10.1016/j.neuint.2021.105221 PMID: 34780806</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Hoffmann, A.; Natoli, G.; Ghosh, G. Transcriptional regulation via the NF-κB signaling module. Oncogene, 2006, 25(51), 6706-6716. doi: 10.1038/sj.onc.1209933 PMID: 17072323</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Dolatshahi, M.; Ranjbar Hameghavandi, M.H.; Sabahi, M.; Rostamkhani, S. Nuclear factor-kappa B (NF-κB) in pathophysiology of Parkinson disease: Diverse patterns and mechanisms contributing to neurodegeneration. Eur. J. Neurosci., 2021, 54(1), 4101-4123. doi: 10.1111/ejn.15242 PMID: 33884689</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Brasier, A.R. The NF-kappaB regulatory network. Cardiovasc. Toxicol., 2006, 6(2), 111-130. doi: 10.1385/CT:6:2:111 PMID: 17303919</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Tergaonkar, V. NF κB pathway: A good signaling paradigm and therapeutic target. Int. J. Biochem. Cell Biol., 2006, 38(10), 1647-1653. doi: 10.1016/j.biocel.2006.03.023 PMID: 16766221</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Pomerantz, J.L.; Baltimore, D. Two Pathways to NF-κ. B. Mol. Cell, 2002, 10(4), 693-695. doi: 10.1016/S1097-2765(02)00697-4 PMID: 12419209</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Songkiatisak, P. Rahman, S.M.T.; Aqdas, M.; Sung, M.H. NF-κB, a culprit of both inflamm-ageing and declining immunity? Immun. Ageing, 2022, 19(1), 20. doi: 10.1186/s12979-022-00277-w PMID: 35581646</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Scheidereit, C. IκB kinase complexes: Gateways to NF-κB activation and transcription Oncogene, 2006, 25(51), 6685-6705. doi: 10.1038/sj.onc.1209934 PMID: 17072322</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Panet, H.; Barzilai, A.; Daily, D.; Melamed, E.; Offen, D. Activation of nuclear transcription factor kappa B (NF-κB) is essential for dopamine-induced apoptosis in PC12 cells. J. Neurochem., 2001, 77(2), 391-398. doi: 10.1046/j.1471-4159.2001.00213.x PMID: 11299301</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Baiguera, C.; Alghisi, M.; Pinna, A.; Bellucci, A.; De Luca, M.A.; Frau, L.; Morelli, M.; Ingrassia, R.; Benarese, M.; Porrini, V.; Pellitteri, M.; Bertini, G.; Fabene, P.F.; Sigala, S.; Spillantini, M.G.; Liou, H.C.; Spano, P.F.; Pizzi, M. Late-onset Parkinsonism in NF B/c-Rel-deficient mice. Brain, 2012, 135(9), 2750-2765. doi: 10.1093/brain/aws193 PMID: 22915735</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Parrella, E.; Bellucci, A.; Porrini, V.; Benarese, M.; Lanzillotta, A.; Faustini, G.; Longhena, F.; Abate, G.; Uberti, D.; Pizzi, M. NF-κB/c-Rel deficiency causes Parkinsons disease-like prodromal symptoms and progressive pathology in mice. Transl. Neurodegener., 2019, 8(1), 16. doi: 10.1186/s40035-019-0154-z PMID: 31139367</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Wang, Z.; Dong, H.; Wang, J.; Huang, Y.; Zhang, X.; Tang, Y.; Li, Q.; Liu, Z.; Ma, Y.; Tong, J.; Huang, L.; Fei, J.; Yu, M.; Wang, J.; Huang, F. Pro-survival and anti-inflammatory roles of NF-κB c-Rel in the Parkinsons disease models. Redox Biol., 2020, 30, 101427. doi: 10.1016/j.redox.2020.101427 PMID: 31986466</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Ghosh, A.; Roy, A.; Liu, X.; Kordower, J.H.; Mufson, E.J.; Hartley, D.M.; Ghosh, S.; Mosley, R.L.; Gendelman, H.E.; Pahan, K. Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinsons disease. Proc. Natl. Acad. Sci. , 2007, 104(47), 18754-18759. doi: 10.1073/pnas.0704908104 PMID: 18000063</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Gan, L.; Li, Z.; Lv, Q.; Huang, W. Rabies virus glycoprotein (RVG29)-linked microRNA-124-loaded polymeric nanoparticles inhibit neuroinflammation in a Parkinsons disease model. Int. J. Pharm., 2019, 567, 118449. doi: 10.1016/j.ijpharm.2019.118449 PMID: 31226473</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Goes, A.T.R.; Jesse, C.R.; Antunes, M.S.; Lobo Ladd, F.V.; Lobo Ladd, A.A.B.; Luchese, C.; Paroul, N.; Boeira, S.P. Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinsons disease: Involvement of neuroinflammation and neurotrophins. Chem. Biol. Interact., 2018, 279, 111-120. doi: 10.1016/j.cbi.2017.10.019 PMID: 29054324</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Jiang, X.; Wang, X.; Tuo, M.; Ma, J.; Xie, A. RAGE and its emerging role in the pathogenesis of Parkinsons disease. Neurosci. Lett., 2018, 672, 65-69. doi: 10.1016/j.neulet.2018.02.049 PMID: 29477598</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Hassanzadeh, K.; Rahimmi, A. Oxidative stress and neuroinflammation in the story of Parkinsons disease: Could targeting these pathways write a good ending? J. Cell. Physiol., 2019, 234(1), 23-32. doi: 10.1002/jcp.26865 PMID: 30078201</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Asanuma, M.; Miyazaki, I.; Ogawa, N. Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinsons disease. Neurotox. Res., 2003, 5(3), 165-176. doi: 10.1007/BF03033137 PMID: 12835121</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Miñones-Moyano, E.; Porta, S.; Escaramís, G.; Rabionet, R.; Iraola, S.; Kagerbauer, B.; Espinosa-Parrilla, Y.; Ferrer, I.; Estivill, X.; Martí, E. MicroRNA profiling of Parkinsons disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum. Mol. Genet., 2011, 20(15), 3067-3078. doi: 10.1093/hmg/ddr210 PMID: 21558425</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Harraz, M.M.; Dawson, T.M.; Dawson, V.L. MicroRNAs in Parkinsons disease. J. Chem. Neuroanat., 2011, 42(2), 127-130. doi: 10.1016/j.jchemneu.2011.01.005 PMID: 21295133</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Correddu, D.; Leung, I.K.H. Targeting mRNA translation in Parkinsons disease. Drug Discov. Today, 2019, 24(6), 1295-1303. doi: 10.1016/j.drudis.2019.04.003 PMID: 30974176</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Martín-Nieto, J.; Uribe, M.L.; Esteve-Rudd, J.; Herrero, M.T.; Campello, L. A role for DJ-1 against oxidative stress in the mammalian retina. Neurosci. Lett., 2019, 708, 134361. doi: 10.1016/j.neulet.2019.134361 PMID: 31276729</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Kabaria, S.; Choi, D.C.; Chaudhuri, A.D.; Mouradian, M.M.; Junn, E. Inhibition of miR-34b and miR-34c enhances α-synuclein expression in Parkinsons disease. FEBS Lett., 2015, 589(3), 319-325. doi: 10.1016/j.febslet.2014.12.014 PMID: 25541488</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Yao, L.; Zhu, Z.; Wu, J.; Zhang, Y.; Zhang, H.; Sun, X.; Qian, C.; Wang, B.; Xie, L.; Zhang, S.; Lu, A.G. MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinsons disease. FASEB J., 2019, 33(7), 8648-8665. doi: 10.1096/fj.201900363R PMID: 30995872</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Wu, S.P.; Zhang, J.W.; Ma, J.J.; Li, X.; Qi, Y.W.; Yang, H.Q. The role of miR-146a in MPTP treated mice with Parkinsons disease. Int. J. Clin. Exp. Med., 2019, 12(4), 3668-3676.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Shah, A.; Smith, D.L. Flavonoids in agriculture: Chemistry and roles in, biotic and abiotic stress responses, and microbial associations. Agronomy , 2020, 10(8), 1209. doi: 10.3390/agronomy10081209</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Chen, Y.; Peng, F.; Xing, Z.; Chen, J.; Peng, C.; Li, D. Beneficial effects of natural flavonoids on neuroinflammation. Front. Immunol., 2022, 13, 1006434. doi: 10.3389/fimmu.2022.1006434 PMID: 36353622</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Schmitt-Schillig, S.; Schaffer, S.; Weber, C.C.; Eckert, G.P.; Müller, W.E. Flavonoids and the aging brain. J. Physiol. Pharmacol., 2005, 56(1)(Suppl. 1), 23-36. PMID: 15800383</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Ishige, K.; Schubert, D.; Sagara, Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic. Biol. Med., 2001, 30(4), 433-446. doi: 10.1016/S0891-5849(00)00498-6 PMID: 11182299</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Bellavite, P. Neuroprotective potentials of flavonoids: Experimental studies and mechanisms of action. Antioxidants, 2023, 12(2), 280. doi: 10.3390/antiox12020280 PMID: 36829840</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Behl, T.; Kaur, G.; Sehgal, A.; Zengin, G.; Singh, S.; Ahmadi, A.; Bungau, S. Flavonoids, the family of plant-derived antioxidants making inroads into novel therapeutic design against ionizing radiation-induced oxidative stress in parkinsons disease. Curr. Neuropharmacol., 2022, 20(2), 324-343. doi: 10.2174/1570159X19666210524152817 PMID: 34030619</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Magalingam, K.B.; Radhakrishnan, A.K.; Haleagrahara, N. Protective mechanisms of flavonoids in parkinsons disease. Oxid. Med. Cell. Longev., 2015, 2015, 1-14. doi: 10.1155/2015/314560 PMID: 26576219</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Gao, B.; Chang, C.; Zhou, J.; Zhao, T.; Wang, C.; Li, C.; Gao, G. Pycnogenol protects against rotenone-induced neurotoxicity in PC12 cells through regulating NF-κB-iNOS signaling pathway. DNA Cell Biol., 2015, 34(10), 643-649. doi: 10.1089/dna.2015.2953 PMID: 26203556</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Kumar, S.; Pandey, A.K. Chemistry and biological activities of flavonoids: An overview. ScientificWorldJournal, 2013, 2013, 1-16. doi: 10.1155/2013/162750 PMID: 24470791</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Wang, Q.; Liu, Y.; Zhou, J. Neuroinflammation in Parkinsons disease and its potential as therapeutic target. Transl. Neurodegener., 2015, 4(1), 19. doi: 10.1186/s40035-015-0042-0 PMID: 26464797</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Muhammad, T.; Ikram, M.; Ullah, R.; Rehman, S.; Kim, M. Hesperetin, a citrus flavonoid, attenuates LPS-induced neuroinflammation, apoptosis and memory impairments by modulating TLR4/NF-κB signaling. Nutrients, 2019, 11(3), 648. doi: 10.3390/nu11030648 PMID: 30884890</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Li, Y.; Zeng, Y.; Meng, T.; Gao, X.; Huang, B.; He, D.; Ran, X.; Du, J.; Zhang, Y.; Fu, S.; Hu, G. Farrerol protects dopaminergic neurons in a rat model of lipopolysaccharide-induced Parkinsons disease by suppressing the activation of the AKT and NF-κB signaling pathways. Int. Immunopharmacol., 2019, 75, 105739. doi: 10.1016/j.intimp.2019.105739 PMID: 31351366</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Kim, D.C.; Quang, T.; Oh, H.; Kim, Y.C. Steppogenin isolated from cudrania tricuspidata shows antineuroinflammatory effects via NF-κB and MAPK pathways in LPS-Stimulated BV2 and primary rat microglial cells. Molecules, 2017, 22(12), 2130. doi: 10.3390/molecules22122130 PMID: 29207498</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Manach, C.; Scalbert, A.; Morand, C.; Rémésy, C.; Jiménez, L. Polyphenols: Food sources and bioavailability. Am. J. Clin. Nutr., 2004, 79(5), 727-747. doi: 10.1093/ajcn/79.5.727 PMID: 15113710</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Patel, M.; Singh, S. Apigenin attenuates functional and structural alterations via targeting NF-kB/Nrf2 signaling pathway in LPS-induced parkinsonism in experimental rats. Neurotox. Res., 2022, 40(4), 941-960. doi: 10.1007/s12640-022-00521-7 PMID: 35608813</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Zhang, X.; Yang, Y.; Du, L.; Zhang, W.; Du, G. Baicalein exerts anti-neuroinflammatory effects to protect against rotenone-induced brain injury in rats. Int. Immunopharmacol., 2017, 50, 38-47. doi: 10.1016/j.intimp.2017.06.007 PMID: 28623717</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Lee, E.; Park, H.R.; Ji, S.T.; Lee, Y.; Lee, J. Baicalein attenuates astroglial activation in the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced Parkinsons disease model by downregulating the activations of nuclear factor-κB, ERK, and JNK. J. Neurosci. Res., 2014, 92(1), 130-139. doi: 10.1002/jnr.23307 PMID: 24166733</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Gao, X.; He, D.; Liu, D.; Hu, G.; Zhang, Y.; Meng, T.; Su, Y.; Zhou, A.; Huang, B.; Du, J.; Fu, S. Beta-naphthoflavone inhibits LPS-induced inflammation in BV-2 cells via AKT/Nrf-2/HO-1-NF-κB signaling axis. Immunobiology, 2020, 225(4), 151965. doi: 10.1016/j.imbio.2020.151965 PMID: 32747020</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Habib, C.N.; Mohamed, M.R.; Tadros, M.G.; Tolba, M.F.; Menze, E.T.; Masoud, S.I. The potential neuroprotective effect of diosmin in rotenone-induced model of Parkinsons disease in rats. Eur. J. Pharmacol., 2022, 914, 174573. doi: 10.1016/j.ejphar.2021.174573 PMID: 34656609</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Qi, G.; Mi, Y.; Fan, R.; Li, R.; Liu, Z.; Liu, X. Nobiletin protects against systemic inflammation-stimulated memory impairment via MAPK and NF-κB signaling pathways. J. Agric. Food Chem., 2019, 67(18), 5122-5134. doi: 10.1021/acs.jafc.9b00133 PMID: 30995031</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Meng, H.W.; Shen, Z.B.; Meng, X.S. Leng-Wei; Yin, Z.Q.; Wang, X.R.; Zou, T.F.; Liu, Z.G.; Wang, T.X.; Zhang, S.; Chen, Y.L.; Yang, X.X.; Li, Q.S.; Duan, Y.J. Novel flavonoid 1,3,4-oxadiazole derivatives ameliorate MPTP-induced Parkinsons disease via Nrf2/NF-κB signaling pathway. Bioorg. Chem., 2023, 138, 106654. doi: 10.1016/j.bioorg.2023.106654 PMID: 37300959</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Zhou, X.; Gan, P.; Hao, L.; Tao, L.; Jia, J.; Gao, B.; Liu, J.; Zheng, L.T.; Zhen, X. Antiinflammatory effects of orientin-2"-O-galactopyranoside on lipopolysaccharide-stimulated microglia. Biol. Pharm. Bull., 2014, 37(8), 1282-1294. doi: 10.1248/bpb.b14-00083 PMID: 25087950</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Panche, A.N.; Diwan, A.D.; Chandra, S.R. Flavonoids: An overview. J. Nutr. Sci., 2016, 29, 47. doi: 10.1017/jns.2016.41</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Akinmoladun, A.C.; Famusiwa, C.D.; Josiah, S.S.; Lawal, A.O.; Olaleye, M.T.; Akindahunsi, A.A. Dihydroquercetin improves rotenone-induced Parkinsonism by regulating NF-κB-mediated inflammation pathway in rats. J. Biochem. Mol. Toxicol., 2022, 36(5), e23022. doi: 10.1002/jbt.23022 PMID: 35187747</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Josiah, S.S.; Famusiwa, C.D.; Crown, O.O.; Lawal, A.O.; Olaleye, M.T.; Akindahunsi, A.A.; Akinmoladun, A.C. Neuroprotective effects of catechin and quercetin in experimental Parkinsonism through modulation of dopamine metabolism and expression of IL-1β, TNF-α, NF-κB, IκKB, and p53 genes in male Wistar rats. Neurotoxicology, 2022, 90, 158-171. doi: 10.1016/j.neuro.2022.03.004 PMID: 35337893</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Iwashina, T. Flavonoid properties of five families newly incorporated into the order Caryophyllales. Bull. Natl. Mus. Nat. Sci., 2013, 39(1), 25-51.</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Zhang, F.X.; Xu, R.S. Juglanin ameliorates LPS-induced neuroinflammation in animal models of Parkinsons disease and cell culture via inactivating TLR4/NF-κB pathway. Biomed. Pharmacother., 2018, 97, 1011-1019. doi: 10.1016/j.biopha.2017.08.132 PMID: 29136779</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Lee, M.; McGeer, E.G.; McGeer, P.L. Quercetin, not caffeine, is a major neuroprotective component in coffee. Neurobiol. Aging, 2016, 46, 113-123. doi: 10.1016/j.neurobiolaging.2016.06.015 PMID: 27479153</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Bahar, E.; Kim, J.Y.; Yoon, H. Quercetin attenuates manganese-induced neuroinflammation by alleviating oxidative stress through regulation of apoptosis, iNOS/NF-κB and HO-1/Nrf2 Pathways. Int. J. Mol. Sci., 2017, 18(9), 1989. doi: 10.3390/ijms18091989 PMID: 28914791</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Notarte, K.I.R.; Quimque, M.T.J.; Macaranas, I.T.; Khan, A.; Pastrana, A.M.; Villaflores, O.B.; Arturo, H.C.P.; Pilapil, D.Y.H., IV; Tan, S.M.M.; Wei, D.Q.; Wenzel-Storjohann, A.; Tasdemir, D.; Yen, C.H.; Ji, S.Y.; Kim, G.Y.; Choi, Y.H.; Macabeo, A.P.G. Attenuation of lipopolysaccharide-induced inflammatory responses through inhibition of the NF-κB Pathway and the Increased NRF2 Level by a Flavonol-Enriched n -Butanol Fraction from Uvaria alba. ACS Omega, 2023, 8(6), 5377-5392. doi: 10.1021/acsomega.2c06451 PMID: 36816691</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Wang, Y.H.; Yu, H.T.; Pu, X.P.; Du, G.H. Myricitrin alleviates methylglyoxal-induced mitochondrial dysfunction and AGEs/RAGE/NF-κB pathway activation in SH-SY5Y cells. J. Mol. Neurosci., 2014, 53(4), 562-570. doi: 10.1007/s12031-013-0222-2 PMID: 24510749</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Zheng, L.T.; Ock, J.; Kwon, B.M.; Suk, K. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. Int. Immunopharmacol., 2008, 8(3), 484-494. doi: 10.1016/j.intimp.2007.12.012 PMID: 18279803</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Zhou, J.; Deng, Y.; Li, F.; Yin, C.; Shi, J.; Gong, Q. Icariside II attenuates lipopolysaccharide-induced neuroinflammation through inhibiting TLR4/MyD88/NF-κB pathway in rats. Biomed. Pharmacother., 2019, 111, 315-324. doi: 10.1016/j.biopha.2018.10.201 PMID: 30590319</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation>Dias, M.C.; Pinto, D.C.G.A.; Silva, A.M.S. Plant flavonoids: Chemical characteristics and biological activity. Molecules, 2021, 26(17), 5377. doi: 10.3390/molecules26175377 PMID: 34500810</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation>Yang, J.; Jia, M.; Zhang, X.; Wang, P. Calycosin attenuates MPTP-induced Parkinsons disease by suppressing the activation of TLR/NF-κB and MAPK pathways. Phytother. Res., 2019, 33(2), 309-318. doi: 10.1002/ptr.6221 PMID: 30421460</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation>Zhao, Y.; Sang, Y.; Sun, Y.; Wu, J. Pomiferin exerts antineuroinflammatory effects through activating Akt/Nrf2 pathway and inhibiting NF-κB pathway. Mediators Inflamm., 2022, 2022, 1-11. doi: 10.1155/2022/5824657 PMID: 35418806</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation>Chinta, S.J.; Ganesan, A.; Reis-Rodrigues, P.; Lithgow, G.J.; Andersen, J.K. Anti-inflammatory role of the isoflavone diadzein in lipopolysaccharide-stimulated microglia: implications for Parkinsons disease. Neurotox. Res., 2013, 23(2), 145-153. doi: 10.1007/s12640-012-9328-5 PMID: 22573480</mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation>Bai, Y.; Zhou, J.; Zhu, H.; Tao, Y.; Wang, L.; Yang, L.; Wu, H.; Huang, F.; Shi, H.; Wu, X. Isoliquiritigenin inhibits microglia-mediated neuroinflammation in models of Parkinsons disease via JNK / AKT NFκ/B signaling pathway. Phytother. Res., 2023, 37(3), 848-859. doi: 10.1002/ptr.7665 PMID: 36484427</mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation>Giusti, M.M.; Wrolstad, R.E. Acylated anthocyanins from edible sources and their applications in food systems. Biochem. Eng. J., 2003, 14(3), 217-225. doi: 10.1016/S1369-703X(02)00221-8</mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation>Khoo, H.E.; Azlan, A.; Tang, S.T.; Lim, S.M. Anthocyanidins and anthocyanins: Colored pigments as food, pharmaceutical ingredients, and the potential health benefits. Food Nutr. Res., 2017, 61(1), 1361779. doi: 10.1080/16546628.2017.1361779 PMID: 28970777</mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation>Khan, M.S.; Ali, T.; Kim, M.W.; Jo, M.H.; Chung, J.I.; Kim, M.O. Anthocyanins improve hippocampus-dependent memory function and prevent neurodegeneration via JNK/Akt/GSK3β signaling in LPS-treated adult mice. Mol. Neurobiol., 2019, 56(1), 671-687. doi: 10.1007/s12035-018-1101-1 PMID: 29779175</mixed-citation></ref></ref-list></back></article>
